HBV Mutation Detail Information

Virus Mutation HBV Mutation A17E


Basic Characteristics of Mutations
Mutation Site A17E
Mutation Site Sentence Table 3. Drug resistance mutations observed in the study cohort.Table 4. Genotypic variants observed in the reverse transcriptase domain in the study cohort.Table 5. Polymerase gene mutations in the current study cohort.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region S
Standardized Encoding Gene S  
Genotype/Subtype D
Viral Reference GenotypeA:AF090842.1(Belgium);X51970.1(Germany);LC519823.1(Bangladesh);GenotypeB:LC365289.1(Japan);D00329.1(Japan);AB073846.1(Asia);GenotypeC:X04615.1(Japan);AB014381.1(Japan);LC365290.1(Japan);GenotypeD:FJ904424.1(Tunisia);X65259.1(Italy);M32138.1(France);GenotypeE:X75657.1(Sweden);AB032431.1;GenotypeF:X69798.1(Germany);AB036910.1(India);GenotypeG:AB625343.1(Mexico);AF160501.1(Korea);AB064310.1(Japan);GenotypeH:AY090454.1(Nicaragua);AY090457.1(Japan);SubtypeD1:AB104712.1(Egypt);AB126581.1(Russia);AB222712.1(Uzbekistan);EU594396.1(Kazakhstan);Y07587.1(Germany);AY721612.1(Turkey);AB222713.1(Uzbekistan);AY161157.1(India);X02496.1(Latvia);AY945307.1(India);AF121240.1(Turkey);AY721607.1(Turkey);AY741797.1(Iran);AB246347.1(India);AB188244.1(Uzbekistan);AB246348.1(USA);AF280817.1(China);FJ904424.1(Tunisia);AY721605.1;SubtypeD2:AB267090.1;Z35716.1;AB210822.1;AB109475.1;SubtypeD3:AY233294.1;Y233293.1;AY233292.1;SubtypeD4:AB048701.1;SubtypeD5:AB033559.1;AB033558.1;SubtypeD6:DQ315779.1;AB493845.1;AB493846.1;AB493848.1;SubtypeD7:FJ904436.1;FJ904405.1;FJ904439.1;SubtypeD8:FN594770.1;FN594769.1;SubtypeD9:JN664942.1;JN664919.1;SubtypeD10:AB555496.1
Functional Impact and Mechanisms
Disease Hepatitis B Virus Infection    
Immune -
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information Y
Treatment -
Location Pakistan
Literature Information
PMID 38004634
Title Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients
Author Gohar M,Rehman IU,Ullah A,Khan MA,Yasmin H,Ahmad J,Butt S,Ahmad A
Journal Microorganisms
Journal Info 2023 Oct 24;11(11):2622
Abstract Several nucleotide analogues have been approved for use in treating hepatitis B virus (HBV) infection. Long-term exposure to therapy leads to the emergence of mutations within the HBV DNA polymerase gene, resulting in drug resistance, a major factor contributing to therapy failure. Chronic HBV patients from the Khyber Pakhtunkhwa province, Pakistan, who had completed 6 months of therapy participated in this study. Samples were collected from 60 patients. In this study, the entire reverse transcriptase domain of the HBV polymerase gene was amplified using nested polymerase chain reaction and sequenced. Drug-resistant mutations were detected in nine (22.5%) patients. All of these patients had lamivudine-resistant mutations (rtM204V + L180M), while seven individuals (17.5%) had both lamivudine- plus entecavir-resistant mutations (L180M + M204V + S202G). N236T, a mutation that gives rise to tenofovir and adefovir resistance, was observed in two (5%) patients. T184A, a partial drug-resistant mutation to entecavir, was found in five (12.5%) patients. Furthermore, other genotypic variants (100%) and vaccine escape mutations (5%) were additionally observed. Moreover, pN459Y (35%), pN131D (20%), pL231S (20%), pP130Q (17.5%), pS189Q (12.5%), pP161S (5%), pH160P (2.5%), pT322S (2.5%), and pA223S (2.5%) mutations in the polymerase gene, as well as sA166V (17.5%), sQ181K (12.5%), sV184R (7.5%), sA17E (5%), sP153S/K (5%), sW156C (5%), sC76Y (2.5%), and S132F (2.5%) mutations in the small surface gene, were identified for the first time in this study. Phylogenetic analysis showed that genotype D was predominant amongst the HBV carriers. Subtype D1 was found in most patients, while two patients were subtype D9. These novel findings may contribute to the body of knowledge and have clinical significance for treating and curing HBV infections in Pakistan.
Sequence Data MK213855-MK213894
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.